Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8 + T-cell responses and boosts anti-tumor immunity

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Rodríguez Cruz, Tania G ^a   Liu, Shujuan ^a   Khalili, Jahan S ^a   Whittington, Mayra ^a   Zhang, Minying ^a   Overwijk, Willem ^a   Lizée, Gregory ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; EPITOPE; HLA ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; ARTICLE; BIOAVAILABILITY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CELL TRANSFER; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE CLUSTER; GENETIC VARIABILITY; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR IMMUNITY; ALTERNATIVE RNA SPLICING; ANIMAL; ANTIGEN PRESENTATION; CHEMISTRY; CYTOLOGY; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXON; EXPERIMENTAL MELANOMA; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; LENTIVIRINAE; METABOLISM;

MUS;

ALTERNATIVE SPLICING; ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOPLASM; DENDRITIC CELLS; EPITOPES; EXONS; HLA ANTIGENS; HUMANS; LENTIVIRUS; MELANOMA, EXPERIMENTAL; MICE; SEQUENCE DELETION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80051507042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022939     Document Type: Article

References (30)

1. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA, (2005) Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 207: 145-157.
2. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
3. Palucka K, Ueno H, Fay J, Banchereau J, (2009) Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci 1174: 88-98.
4. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM, (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58: 1-14.
5. Andrews DM, Maraskovsky E, Smyth MJ, (2008) Cancer vaccines for established cancer: how to make them better? Immunol Rev 222: 242-255.
6. Lou Y, Wang G, Lizee G, Kim GJ, Finkelstein SE, et al. (2004) Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64: 6783-6790.
7. Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, et al. (2006) Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 78: 711-718.
8. Luo J, Li J, Chen RL, Nie L, Huang J, et al. (2010) Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 28: 2497-2504.
9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332.
10. Rosenberg SA, Yang JC, Restifo NP, (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
11. Melief CJ, (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
12. Capps GG, Van Kampen M, Ward CL, Zuniga MC, (1989) Endocytosis of the class I major histocompatibility antigen via a phorbol myristate acetate-inducible pathway is a cell-specific phenomenon and requires the cytoplasmic domain. J Cell Biol 108: 1317-1329.
13. Abdel Motal UM, Sentman CL, Zhou X, Robinson PJ, Dahmen J, et al. (1995) Glycosylphosphatidylinositol-linked Db does not induce an influenza-specific cytotoxic T lymphocyte response or recycle membrane-bound peptides. Eur J Immunol 25: 1121-1124.
14. Lizee G, Basha G, Tiong J, Julien JP, Tian M, et al. (2003) Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol 4: 1065-1073.
15. Basha G, Lizee G, Reinicke AT, Seipp RP, Omilusik KD, et al. (2008) MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. PLoS ONE 3: e3247.
16. Ellis SA, Braem KA, Morrison WI, (1992) Transmembrane and cytoplasmic domain sequences demonstrate at least two expressed bovine MHC class I loci. Immunogenetics 37: 49-56.
17. McCluskey J, Boyd LF, Maloy WL, Coligan JE, Margulies DH, (1986) Alternative processing of H-2Dd pre-mRNAs results in membrane expression of differentially phosphorylated protein products. Embo J 5: 2477-2483.
18. Guild BC, Strominger JL, (1984) Human and murine class I MHC antigens share conserved serine 335, the site of HLA phosphorylation in vivo. J Biol Chem 259: 9235-9240.
19. Pober JS, Guild BC, Strominger JL, (1978) Phosphorylation in vivo and in vitro of human histocompatibility antigens (HLA-A and HLA-B) in the carboxy-terminal intracellular domain. Proc Natl Acad Sci U S A 75: 6002-6006.
20. Dalgaard TS, Vitved L, Skjodt K, Thomsen B, Labouriau R, et al. (2005) Molecular characterization of major histocompatibility complex class I (B-F) mRNA variants from chickens differing in resistance to Marek's disease. Scand J Immunol 62: 259-270.
21. Vega MA, Strominger JL, (1989) Constitutive endocytosis of HLA class I antigens requires a specific portion of the intracytoplasmic tail that shares structural features with other endocytosed molecules. Proc Natl Acad Sci U S A 86: 2688-2692.
22. Lizee G, Basha G, Jefferies WA, (2005) Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation. Trends Immunol 26: 141-149.
23. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, et al. (1999) Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A 96: 10326-10331.
24. Ackerman AL, Kyritsis C, Tampe R, Cresswell P, (2003) Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci U S A 100: 12889-12894.
25. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C, (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9: 558-566.
26. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580.
27. Ackerman AL, Cresswell P, (2003) Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J Immunol 170: 4178-4188.
28. Capps GG, Zuniga MC, (2000) Phosphorylation of class I MHC molecules in the absence of phorbol esters is an intracellular event and may be characteristic of trafficking molecules. Mol Immunol 37: 59-71.
29. Santos SG, Powis SJ, Arosa FA, (2004) Misfolding of major histocompatibility complex class I molecules in activated T cells allows cis-interactions with receptors and signaling molecules and is associated with tyrosine phosphorylation. J Biol Chem 279: 53062-53070.
30. Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K, Fruh K, (2004) Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol 78: 1109-1120.